Takeda Pharmaceutical Co. Ltd. · TSE:4502
Takeda Pharmaceutical — Investor Day (December 2023)
21 slides from Takeda Pharmaceutical's investor day presentation, Dec 5, 2023
Slide 1: Leading Sustainable Growth Through End-to-End Innovation
Leading Sustainable Growth Through End-to-End Innovation 5 December 2023 ET 6 December 2023 JT
Slide 2: Important Notice
Important Notice For the purposes of this notice, “presentation” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this presentation. This presentation (i
Slide 3: Our team
Our team Giles Platford Ramy Riad Kristina Allikmets Hema Tallman Abbas Yar-Khan President, Plasma- Chief Financial Head of Research Global Head of Head of Plasma Derived Therapies Officer, PDT BU & Development, BioLife, Operating Unit, BU (PDT BU) PDT BU PDT BU Global Manufacturing & Supply 3
Slide 4: What we will cover today
What we will cover today What we have accomplished - and how What the future looks like - and why You will see that we: • Continue to deliver industry-leading performance across all key parameters • Have robust plans in place to build on this momentum and create more value • Are delivering for share
Slide 5: Our industry-leading performance has delivered for patients
Our industry-leading performance has delivered for patients, demonstrating we have the right strategy, the right team and the right capabilities in place ACCELERATED expansion Delivered on capacity FASTER THAN MARKET of plasma network expansion 12 MONTHS EARLY revenue growth +88% >65% +9% PDT revenu
Slide 6: We achieved our capacity expansion target one year early
We achieved our capacity expansion target one year early through targeted investment in new and upgraded manufacturing infrastructure MANUFACTURING CAPACITY >65% Enhanced fractionation capacity across our network: • Ramp up of Covington since 2018 • Equipment & utility expansion in Vienna and Rieti
Slide 7: Strategic investment and technology-led transformation across our BioLife plasma donation network
This achievement was bolstered by strategic investment and technology- led transformation across our BioLife plasma donation network • 100+ new donation centers since 2018 • Industry leading high efficiency Aurora XI machines rolled out to 30% of centers • Footprint expanded to 11 new US States NETW
Slide 8: Our outstanding revenue growth shows the strength of our broad and differentiated portfolio
Our outstanding revenue growth shows the strength of our broad and differentiated portfolio Consistent revenue growth accelerated by geographic and indication expansion PDT BU FY2022 Reported Revenue 11% Average yearly growth4 Product Family 3 years FY2020 - FY2022 5% Total PDT +9% Total 16% 762.1B
Slide 9: >160 approvals, 72 geographies for 13 PDTs
Our sustained portfolio growth is fueled by our patient-focused approach and strong momentum in R&D >160 approvals 72 geographies for 13 PDTs Significant progress since FY2019 70% 30 of approvals were regulatory applications First Liters under review • HyQvia approved for pediatric PID in US • US an
Slide 10: Data, Digital & Technology is driving innovative transformation across the value chain
Data, Digital & Technology is driving innovative transformation across the value chain, bringing excellence, agility and efficiencies Elevating donation experience Leveraging AI/ML Improving patient care experience increases plasma volume delivers operational efficiencies drives value • Personalized
Slide 11: Greater efficiencies and higher revenue growth with less capacity than our peers
We have delivered greater efficiencies and higher revenue growth with less capacity than our peers through operational excellence and transformation Takeda IG Revenue Growth1 ~30% additional revenue growth from efficiencies in 2020-2022 +10 – 20% Value Recognition +16% +9% IG Yield from +16% 1L of P
Slide 12: Our FY2023 PDT BU guidance is confirmed by robust H1 financial results
Our FY2023 PDT BU guidance is confirmed by robust H1 financial results H1 FY2023 Revenue Growth @ CER PDT BU PDT IMMUNOLOGY IG PORTFOLIO ALBUMIN PORTFOLIO +14% +17% +19% +11% 428.4B JPY 388.4B JPY 309.2B JPY 58.9B JPY $2.9 B USD1 $2.6 B USD1 $2.1 B USD1 $0.4 B USD1 FY2023 PDT BU Revenue Growth Guida
Slide 13: We will continue to power up sustainable growth through end-to-end innovation
We will continue to power up sustainable growth through end- to-end innovation 13
Slide 14: Significant unmet patient needs are driving sustained PDT market growth
Significant unmet patient needs across many chronic and rare diseases are driving sustained PDT market growth despite headwinds Increasing Demand Major Market Dynamics Worldwide IG therapies market is increasing yearly • Increasing diagnosis rates • Geographic expansion & access to care • Need for i
Slide 15: New target to increase manufacturing capacity by >50% from FY2023 to end of FY2028
We have set a new target to increase manufacturing capacity by >50% from FY2023 to end of FY2028 1 Expansion of facilities and utilities across all sites Lessines, Belgium New manufacturing capacity target Round Lake, USA Ig purification line and Flexbumin filling and warehouse Vienna, Austria >50%
Slide 16: A holistic approach to increasing plasma donation
We are taking a holistic approach to increasing plasma donation that is redefining industry standards and bringing greater efficiencies DONOR • Comprehensive Customer WORKFORCE • Transformed Workforce MODERNIZED • Intelligent Donor Care Experience (CX) Management System platform automates EXPERIENCE
Slide 17: Our PDT portfolio strategy is positioned to drive sustainable long-term growth
Our PDT portfolio strategy is positioned to drive sustainable long-term growth in a dynamic market through innovations that address unmet patient needs SERVE MORE PATIENTS REDEFINE EXPERIENCE UNLOCK PLASMA POTENTIAL Serve more patients across indications & Deliver improved formulations and patient-c
Slide 18: Long-term IG growth potential remains strong despite new modalities in neuroimmunology
Long-term IG growth potential remains strong despite the entry of new modalities in neuroimmunology indications IG Usage (2022 estimates, by volume, global) IG remains standard of care in chronic inflammatory demyelinating polyneuropathy (CIDP) CIDP is a heterogeneous disease with a lack of clear ma
Slide 19: We are proud of our sustained success and our planned investment
We are proud of our sustained success - and our planned investment underscores our confidence and drives our continued commitment to creating value Robust sustainable topline growth through: • Meeting high unmet patient needs • Sharper PDT portfolio strategy >50% Manufacturing capacity • Facility ex
Slide 20: Leading Sustainable Growth Through End-to-End Innovation
Leading Sustainable Growth Through End-to-End Innovation 5 December 2023 ET 6 December 2023 JT
Slide 21: Glossary of Terms (In Alphabetical Order)
Glossary of Terms (In Alphabetical Order) A1ATD Alpha-1 Antitrypsin Deficiency ITP Immune Thrombocytopenic Purpura BU Business Unit IVIG Intravenous Immunoglobulin CIDP Chronic Inflammatory Demyelinating Polyneuropathy Kawasaki Kawasaki Disease CPL Cost Per Liter MG Myasthenia Gravis DD&T Data, Digi
Takeda Pharmaceutical Company — Investor Day (December 2023) on 6ix